[Securing the primary effect in experiments with chemical carcinogens].
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D000951:Antigens, Neoplasm / Q000096:biosynthesis; D050260:Carbohydrate Metabolism; D002273:Carcinogens; D002471:Cell Transformation, Neoplastic; D002478:Cells, Cultured; D002875:Chromosomes / Q000378:metabolism; D004247:DNA / Q000378:metabolism; D004622:Embryo, Mammalian / Q000378:metabolism; D004625:Embryo, Nonmammalian; D005796:Genes / Q000187:drug effects; D005809:Genes, Regulator / Q000187:drug effects; D009154:Mutation / Q000187:drug effects; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009369:Neoplasms / Q000201:enzymology; D009374:Neoplasms, Experimental / Q000139:chemically induced* / Q000378:metabolism; D009924:Organ Culture Techniques; D011230:Precancerous Conditions; D012334:RNA, Neoplasm / Q000378:metabolism; D004124:p-Dimethylaminoazobenzene
D000951:Antigens, Neoplasm; D002273:Carcinogens; D009363:Neoplasm Proteins; D012334:RNA, Neoplasm; D015127:9,10-Dimethyl-1,2-benzanthracene; D004247:DNA; D004124:p-Dimethylaminoazobenzene
Zakreplenie pervichnogo éffekta v opytakh s khimicheskimi kantserogenami